Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07609316
Recruiting Not applicable

Effectiveness of a Culturally Adapted Online Education Program (iSupport-Korea) for Family Caregivers of People With Dementia

NCT07609316 · tracked via the Priya Life Science South Korea tracker
Sponsor
Chungnam National University
Phase
Not applicable
Started
2026-05-13
Last updated
2026-05-27

Condition(s) studied

Dementia

Investigational drug(s) / intervention(s)

iSupport-KoreaDementia information website

iSupport-Korea: iSupport-Korea is a culturally adapted online education and support program for family caregivers of people with dementia. It is designed to enhance caregiver self-efficacy, coping strategies, and overall quality of life through a self-directed learning approach.

Dementia information website: The control condition consists of access to publicly available dementia-related informational websites.

Study summary

This randomized controlled trial evaluates the effectiveness of iSupport-Korea, a culturally adapted online education program for family caregivers of people with dementia. A total of 160 caregivers will be randomly assigned to either the intervention or control group and followed for 4 months. The investigators hypothesize that the intervention group will show greater improvements in care-related quality of life, caregiver self-efficacy, and family decision-making self-efficacy.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged 19 years or older * Family caregivers currently providing care for a person diagnosed with dementia * Informal caregivers such as spouse, children, or relatives * Living with the person with dementia or providing regular care even if not cohabiting * Able to read and understand Korean and communicate in Korean * Able to use digital devices (e.g., smartphone, tablet, or computer) to access an online program * Willing to provide informed consent and participate in the study Exclusion Criteria: * Not currently providing direct care to a person with dementia * Participating in another dementia caregiver intervention or similar study * Having severe cognitive impairment, psychiatric illness, or communication difficulties that limit participation * Having severe visual or hearing impairment that interferes with program use * Unable to complete follow-up assessments during the study period

Primary outcome measure(s)

  • Change in subjective well-being (CarerQol-VAS) — Baseline, 2 months, and 4 months
    Subjective well-being will be measured using the CarerQol-VAS, a visual analogue scale ranging from 0 to 10, with higher scores indicating greater well-being
  • Change in care-related quality of life (CarerQol-7D) — Baseline, 2 months, and 4 months
    Care-related quality of life will be measured using the Carer-related Quality of Life instrument-7 Dimensions (CarerQol-7D), which assesses caregiving burden across seven dimensions. Each dimension is rated on a 3-level scale (no, some, or a lot of problems), with higher scores indicating better care-related quality of life.

Trial sites (1)

FacilityCityRegionStatus
College of Nursing, Chungnam National University Daejeon Jung-gu, Daejeon Recruiting

More Chungnam National University trials in South Korea

Development and Evaluation of an Online Shared Decision-Making Educational Program for Nurses and Patients With Chronic Diseases Recruiting

Other trials for the same condition

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation Recruiting
Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ) Recruiting
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation Recruiting
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07609316 on ClinicalTrials.gov ↗ ← All trials in South Korea